Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olsson

Showing results (621-630 of 632) with videos related to

Pageof 64
Sort By:
Journal of the American College of Cardiology|December 3, 2016
Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive ProteinReynaria Pitts, Elise Gunzburger, Christie M Ballantyne, et al.
American Heart Journal|December 5, 2009
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Christie M Ballantyne, et al.
Journal of the American College of Cardiology|February 12, 2008
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studiesWim A van der Steeg, Ingar Holme, S Matthijs Boekholdt, et al.
Circulation. Cardiovascular Genetics|July 16, 2016
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical OutcomesJean-Claude Tardif, David Rhainds, Mathieu Brodeur, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of Internal Medicine|March 16, 2017
Can LDL cholesterol be too low? Possible risks of extremely low levelsA G Olsson, B Angelin, G Assmann, et al.
Nature Genetics|March 8, 2005
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibilityXiaosong Wang, Massimiliano Ria, Peter M Kelmenson, et al.
The New England Journal of Medicine|November 7, 2012
Effects of dalcetrapib in patients with a recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Markus Abt, et al.
BMC Genomics|March 22, 2021
Rust expression browser: an open source database for simultaneous analysis of host and pathogen gene expression profiles with expVIPThomas M Adams, Tjelvar S G Olsson, Ricardo H Ramírez-González, et al.
Pageof 64

Showing results (621-630 of 632) with videos related to

Sort By:
Pageof 64
Journal of the American College of Cardiology|December 3, 2016
Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive ProteinReynaria Pitts, Elise Gunzburger, Christie M Ballantyne, et al.
American Heart Journal|December 5, 2009
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Christie M Ballantyne, et al.
Journal of the American College of Cardiology|February 12, 2008
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studiesWim A van der Steeg, Ingar Holme, S Matthijs Boekholdt, et al.
Circulation. Cardiovascular Genetics|July 16, 2016
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical OutcomesJean-Claude Tardif, David Rhainds, Mathieu Brodeur, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of Internal Medicine|March 16, 2017
Can LDL cholesterol be too low? Possible risks of extremely low levelsA G Olsson, B Angelin, G Assmann, et al.
Nature Genetics|March 8, 2005
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibilityXiaosong Wang, Massimiliano Ria, Peter M Kelmenson, et al.
The New England Journal of Medicine|November 7, 2012
Effects of dalcetrapib in patients with a recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Markus Abt, et al.
BMC Genomics|March 22, 2021
Rust expression browser: an open source database for simultaneous analysis of host and pathogen gene expression profiles with expVIPThomas M Adams, Tjelvar S G Olsson, Ricardo H Ramírez-González, et al.
Pageof 64